- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04820972
Early-Start Antiplatelet Treatment After Neurosurgery in Patients With Spontaneous Intracerebral Hemorrhage
February 23, 2022 updated by: Wang Shuo, Beijing Tiantan Hospital
This study is a multicenter, prospective, open-label, endpoint-blind, randomized controlled study.Patients receiving surgical treatment for SICH were divided into groups using the random machine method.
In addition to conventional treatment for spontaneous intracerebral hemorrhage, patients in the group of early initiation of antiplatelet therapy were given conventional dose of aspirin (100mg, qd) antiplatelet therapy starting from the 3rd day after surgery.An independent group of investigators evaluated cardiac, cerebral and peripheral vascular events and bleeding events at four different time points.To evaluate the benefits and safety of early postoperative initiation of antiplatelet therapy in patients with spontaneous intracerebral hemorrhage.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: JUN WU, MD
- Phone Number: +8613426322945
- Email: wujunslf@126.com
Study Contact Backup
- Name: Shuo Wang, MD
- Phone Number: 13801180330
- Email: captain9858@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Capital Medical University Affiliated Beijing Tiantan Hospital
-
Contact:
- JUN WU, MD
- Phone Number: +8613426322945
- Email: wujunslf@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18-70 years old.
- nontraumatic spontaneous intracerebral hemorrhage.
- postoperative patients with high risk of MACCPE:(1)previous history of cerebral infarction or TIA. (2)previous history of coronary heart disease or myocardial infarction.(3) use ASCVD Risk Estimator Plus(http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/) to assess the risk of ischemic events for patients with no previous history of cerebral infarction, TIA, or coronary heart diseases or myocardial infarction,10 years risk>10% is defined as a high risk of cardiovascular ischemic events(4)The Caprini Risk Scale is used to assess the risk of venous thrombosis in the lower extremities.Score>2 is defined as a high risk of venous thrombosis.
- patients who received neurosurgical procedures to remove the hematoma, including craniotomy, endoscopic hematoma removal and hematoma aspiration.
- patients who signed informed consent.
- no history of allergy to salicylic acid preparation.
- patients who complete the preintervention assessment and meet the fellow criteria:(1)postoperative head CT showed no new infarction or hemorrhage(2)postoperative venous ultrasound of the lower extremity did not reveal deep vein thrombosis.(3)postoperative electrocardiogram and myocardial enzyme examination did not show acute myocardial ischemia or myocardial infarction.
Exclusion Criteria:
- there are structural cerebrovascular lesions (such as intracranial aneurysms, cerebrovascular malformations, etc.) or tumors in the area of bleeding or the bleeding is suspected to be related to these lesions.
- ischemic stroke with hemorrhagic conversion.
- secondary bleeding due to venous embolism.
- the malignant tumor is expected to have a survival of no more than 3 months.
- take antithrombotic agents((Vitamin K antagonists (warfarin) new anticoagulants(Dabigatun Rivaroxaban))) in addition to antiplatelet agents.
- previous history of thrombocytopenia or coagulation disorders.
- previous history of atrial fibrillation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E-STAR group
|
using antiplatelet agents in 3 days after surgery
|
No Intervention: traditional group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
rate of intracranial hemorrhage
Time Frame: 7 days after surgery
|
7 days after surgery
|
rate of intracranial hemorrhage
Time Frame: 14 days after surgery
|
14 days after surgery
|
rate of intracranial hemorrhage
Time Frame: 30 days after surgery
|
30 days after surgery
|
rate of intracranial hemorrhage
Time Frame: 90 days after surgery
|
90 days after surgery
|
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time Frame: 7 days after surgery
|
7 days after surgery
|
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time Frame: 14 days after surgery
|
14 days after surgery
|
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time Frame: 30 days after surgery
|
30 days after surgery
|
rate of major adverse cardiac/cerebrovascular and peripheral vessel events
Time Frame: 90 days after surgery
|
90 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Shuo Wang, MD, Beijing Tiantan Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2021
Primary Completion (Anticipated)
February 1, 2023
Study Completion (Anticipated)
May 1, 2023
Study Registration Dates
First Submitted
March 24, 2021
First Submitted That Met QC Criteria
March 25, 2021
First Posted (Actual)
March 29, 2021
Study Record Updates
Last Update Posted (Actual)
March 10, 2022
Last Update Submitted That Met QC Criteria
February 23, 2022
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HX-A-007(2021)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spontaneous Intracerebral Hemorrhage
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
First Affiliated Hospital of Fujian Medical UniversityLanZhou University; Shaanxi Provincial People's Hospital; Fifth Affiliated Hospital... and other collaboratorsRecruitingTreatment of Spontaneous Intracerebral HemorrhageChina
-
First Affiliated Hospital of Fujian Medical UniversityNational Health and Family Planning Commission, P.R.ChinaRecruitingSpontaneous Intracerebral HemorrhageChina
-
Beijing Tiantan HospitalRecruitingSpontaneous Intracerebral HemorrhageChina
-
Beijing Tiantan HospitalBeijing Friendship Hospital; Beijing Chao Yang Hospital; Beijing Anzhen Hospital and other collaboratorsRecruitingComplications | Emergency Surgery | Severe Spontaneous Intracranial Hemorrhage | Long-term Antiplatelet TreatmentChina
-
Beijing Tiantan HospitalBeijing Chao Yang Hospital; Beijing Anzhen Hospital; Guangzhou Red Cross Hospital and other collaboratorsCompletedComplications | Emergency Surgery | Severe Spontaneous Intracranial Hemorrhage | Long-term Antiplatelet TreatmentChina
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
University Hospital, Basel, SwitzerlandSwiss Heart FoundationActive, not recruitingIntracerebral Hemorrhage (ICH)Switzerland
-
AegisCN LLCCompletedIntracerebral Hemorrhage (ICH)United States
-
Tongji HospitalUnknown
Clinical Trials on Antiplatelet Agents
-
Josep Rodes-CabauRecruitingIschemic Stroke | Patent Foramen Ovale | Bleeding UlcerCanada
-
Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
National Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
Centre Hospitalier Universitaire de Saint EtienneNot yet recruiting
-
Sichuan Provincial People's HospitalRecruitingIschemic Stroke | Antiplatelet DrugChina
-
China National Center for Cardiovascular DiseasesRecruitingMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Bleeding | Angina Pectoris | Dual Antiplatelet Therapy | Coronary Artery Bypass GraftingChina
-
State University of New York - Upstate Medical...CompletedIschemic Stroke | TIAUnited States
-
University of Roma La SapienzaNot yet recruitingCoronary Artery Disease
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University Medical...RecruitingStroke | Atrial Fibrillation | BleedingUnited States, United Kingdom, Canada, Germany
-
Seoul National University HospitalLudwig-Maximilians - University of Munich; ST. Antonius hospital NieuwegeinRecruitingCoronary Artery Disease | Acute Coronary SyndromeKorea, Republic of